Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023;19(8):e090123212444.
doi: 10.2174/1573399819666230109104300.

Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era

Abhishek Shrivastava  1 , Jothydev Kesavadev  2 , Viswanathan Mohan  3 , Banshi Saboo  4 , Dina Shrestha  5 , Anuj Maheshwari  6 , Brij Mohan Makkar  7 , Kirtikumar D Modi  8 , Ashok Kumar Das  9
Affiliations
Review

Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era

Abhishek Shrivastava et al. Curr Diabetes Rev. 2023.

Abstract

Background and aim: Basal insulin combined oral therapy consisting of insulin and oral anti-diabetic drugs (OADs) is recommended for type 2 diabetes uncontrolled on OADs. There is a lack of clear evidence and recommendations on the combined use of basal insulin analogues to more than one OADs (glimepiride plus metformin) in effective control of glycemic parameters and its safety in terms of reduced hypoglycemic events, weight gain and cardiovascular risk. In this context, a group of clinical experts discussed the utility of basal insulin combined oral therapy with metformin and glimepiride in the current era.

Methods: The clinical experts discussed and provided their inputs virtually. The expert panel included clinical experts comprising endocrinologists and diabetologists from India and Nepal.

Results: The panel thoroughly reviewed existing literature on the subject and proposed clinical evidence and practice-based guidelines.

Conclusion: These current clinical practice guidelines highlight the efficacy and safety of basal insulin combination therapy with various available basal insulins including neutral protamine hagedorn, detemir, glargine and degludec in addition to metformin and glimepiride therapy.

Keywords: Degludec; anti-diabetic drugs; glargine; glimepiride; metformin; oral.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Figures

Fig. (1)
Fig. (1)
Synergistic mechanism of action and clinical benefits of metformin and glimepiride combination [11].
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Khursheed R., Singh S.K., Wadhwa S., et al. Treatment strategies against diabetes: Success so far and challenges ahead. Eur. J. Pharmacol. 2019;862:172625. doi: 10.1016/j.ejphar.2019.172625. - DOI - PubMed
    1. Das A.K., Mithal A., Joshi S., et al. Baseline characteristics of participants in the LANDMARC trial: A 3‐year, pan ‐India, prospective, longitudinal study to assess management and real‐world outcomes of diabetes mellitus. Endocrinol. Diabetes Metab. 2021;4(3):e00231. doi: 10.1002/edm2.231. - DOI - PMC - PubMed
    1. Suzuki D., Umezono T., Miyauchi M., et al. Effectiveness of Basal-Supported Oral Therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes. Tokai J. Exp. Clin. Med. 2012;37(2):41–46. - PubMed
    1. Danne T., Bluhmki T., Seufert J., et al. Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registry. BMC Endocr. Disord. 2015;15(1):54. doi: 10.1186/s12902-015-0051-0. - DOI - PMC - PubMed
    1. Sorli C., Heile M.K. Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J. Multidiscip. Healthc. 2014;7:267–282. doi: 10.2147/JMDH.S64084. - DOI - PMC - PubMed
  NODES
INTERN 2
twitter 2